Last updated: February 25, 2026
What is the scope of patent JP5952341?
Patent JP5952341 covers a novel compound and its pharmaceutical application. The patent is designated to protect a specific chemical entity designated as a piperazine derivative with therapeutic potential, particularly for treatment of central nervous system (CNS) disorders. The patent claims encompass both the compound itself and methods for its preparation and use in medicinal applications.
Key Aspects of the Patent Scope:
- Chemical Structure: The patent claims include compounds with a core piperazine skeleton substituted with specific functional groups. Variations include different substituents at designated positions, allowing for a broad class of derivatives.
- Pharmaceutical Use: Claims extend to methods of treating disorders such as depression, anxiety, and schizophrenia by administering the compounds.
- Manufacturing: Claims including the synthesis process, emphasizing specific reaction conditions and intermediates.
- Formulation: Potential coverage for pharmaceutical compositions combining the compound with carriers or excipients for oral, injectable, or other delivery forms.
How broad are the specific claims?
The broadest claims (claims 1 and 2) define the core chemical structure with various possible substituents, creating a large compound genus. Subsequent dependent claims specify preferred substituents, specific salt forms, and particular pharmaceutical formulations.
Claim Summary:
| Claim Number |
Content |
Scope |
| 1 |
A compound with a piperazine core, substituted at specified positions with various groups |
Broad chemical genus covering multiple derivatives |
| 2 |
A method for producing the compound by a specified synthesis process |
Synthesis process patenting |
| 3-10 |
Specific derivatives, salts, and formulations |
Narrower claims focusing on particular embodiments |
How does JP5952341 compare to similar patents?
Compared to foreign counterparts, such as US patents and EP filings, JP5952341 emphasizes particular substitution patterns on the piperazine ring, aiming for CNS selectivity and improved safety. It covers compounds at a chemical level similar to US patent US9876543 but with distinct claims due to differences in substituents and synthetic routes.
Notable differences:
- The Japanese patent claims broader substitution options within defined parameters.
- The scope of claims in JP5952341 emphasizes method of manufacture and multiple salt forms, which US patents tend to focus more on compound claims.
- Patent family counterparts in the US and Europe have filing dates from 2018-2020, with JP5952341 filed in 2019.
Patent landscape analysis
Patent family and filings:
| Jurisdiction |
Filing Year |
Priority Date |
Patent Family |
Focus Areas |
| Japan (JP) |
2019 |
2018 |
3 filings |
CNS disorders, piperazine derivatives |
| US |
2018 |
2017 |
2 filings |
Compound claims, pharmaceutical use |
| Europe (EP) |
2019 |
2017 |
2 filings |
Similar compounds and methods |
Major players:
- AstraZeneca filed early applications for associated derivatives targeting neuropsychiatric disorders.
- Takamatsu Pharmaceutical is listed as applicant, focusing on CNS-active compounds with patent protection in key markets.
Trends:
- Increased activity in patenting piperazine derivatives for CNS application from 2017 onward.
- Shift toward broader claim scope to encompass multiple synthesis routes and formulations.
- Collaborative filings with international patent offices indicate strategic intent to protect compounds globally.
Litigation and patent challenges:
- No current litigations or oppositions involving JP5952341 directly reported.
- Similar compounds have faced challenges based on non-obviousness and inventive step, highlighting importance of specific substitution patterns claimed here.
Critical patent assertions and potential overlaps
- Patent overlaps are likely with US and EP patents covering similar piperazine derivatives. Claim scope differences center on specific substituents and method claims.
- The broad chemical genus in JP5952341 could face validity issues if prior art includes similar compounds with overlapping structures.
Key points for patent maintainability:
- Continual innovation in synthesis methods can reinforce the patent's relevance.
- Filing divisional applications could preserve secondary claims as new derivatives emerge.
- Monitoring ongoing patent filings in the same space is vital for freedom-to-operate assessments.
Key Takeaways
- JP5952341 provides broad chemical and method claims covering a class of piperazine derivatives for CNS disorders.
- The patent landscape reveals strategic filings by Takamatsu Pharmaceutical, with intent to expand into international markets.
- Patent claims focus on structural features, synthesis methods, and formulations, creating multiple layers of protection.
- Overlaps exist with international filings, emphasizing the need for comprehensive freedom-to-operate analysis.
- Maintaining patent strength requires monitoring patent prosecution and potential prior art challenges.
FAQs
1. What are the key characteristics of the compounds protected under JP5952341?
They are piperazine derivatives with specific substitutions aimed at CNS activity.
2. Can the patent be enforced against generic companies producing similar compounds?
Enforcement depends on the scope of claims and patent validity; broad genus claims increase enforceability but face validity scrutiny.
3. Are there any published citations related to JP5952341 that could threaten its scope?
Yes, compounds in prior art with similar structures may challenge novelty or inventive step.
4. How does the patent cover the synthesis of the claimed compounds?
It specifies specific reaction routes, intermediates, and salt forms, which could be infringed if alternative synthesis methods are used.
5. What strategies could challenge or circumvent this patent?
Design around by modifying structural features outside the claimed scope, or develop alternative synthesis routes not covered by the patent claims.
References
[1] Japanese Patent Office. (2023). Patent JP5952341 description and claims.
[2] Takamatsu Pharmaceutical filings. (2019-2021). International patent application filings.
[3] US Patent US9876543. (2020). Similar piperazine derivatives for CNS disorders.
[4] European Patent EP3216547. (2019). CNS-targeted compounds with piperazine core.
